STOCK TITAN

Alcon Inc. - ALC STOCK NEWS

Welcome to our dedicated news page for Alcon (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alcon's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alcon's position in the market.

Rhea-AI Summary
Alcon (ALC) reported strong financial results for Q4 2023, with sales of $2.3 billion, up 8% or 10% constant currency, and diluted EPS of $0.86. FY 2023 sales were $9.4 billion, up 8%, and diluted EPS was $1.96. The company projects 6-8% sales growth and 13-16% core diluted EPS growth for FY 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
earnings
-
Rhea-AI Summary
Alcon has launched TOTAL30 Multifocal, the first monthly Water Gradient multifocal contact lens that provides excellent visual acuity at all distances, addressing the needs of the growing global multifocal market. The lens helps outsmart digital device dryness and presbyopia, which affects nearly 80% of people aged 45-55. The company aims to offer premium Water Gradient innovation at an accessible price point, with a proven fit success rate of 96%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
none
-
Rhea-AI Summary
Alcon (ALC) announced positive topline results from the two pivotal Phase 3 clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of dry eye disease (DED). In both trials, the primary endpoint of the proportion of subjects with at least a 10-mm increase in unanesthetized Schirmer’s score achieved statistical significance at Day 14 [p<0.0001]. Dry eye affects an estimated 38 million people in the U.S. and less than 10% of diagnosed patients are treated with a prescription product. AR-15512 has the potential to address the limitations of current dry eye prescription options and provide Eye Care Professionals (ECPs) and dry eye sufferers with a new and effective approach to the management of dry eye, a chronic and undertreated disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.54%
Tags
clinical trial
Rhea-AI Summary
Alcon (ALC) CEO David Endicott to Present at 2024 J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
conferences
-
News
Rhea-AI Summary
Alcon (SIX/NYSE:ALC) reports strong Q3 2023 financial results with $2.3 billion in sales, up 8%, or 9% constant currency. Diluted EPS increased by 78%, or up 97% cc, and core diluted EPS up by 32%, or 41% cc. Operating margin improved by 3.0 percentage points, and the company generated $937 million of cash from operating activities and $592 million of free cash flow in the first nine months of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.91%
Tags
earnings
-
Rhea-AI Summary
Alcon: Clareon Vivity, the first non-diffractive EDOF IOL with X-WAVE Technology, is now available in Canada, offering high-quality vision and spectacle independence for cataract patients. Surgeons can now provide patients with a lens designed to deliver optimal outcomes, comparable to a monofocal IOL, while minimizing visual disturbances. The lens features X-WAVE technology and glistening-free material, offering excellent distance, intermediate, and functional near vision.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
none
Rhea-AI Summary
Alcon announces full U.S. commercial availability of cloud-based cataract planner, SMARTCataract, which offers seamless connectivity for surgical ophthalmic practices. The platform has demonstrated significant time savings during the cataract evaluation, planning process, operating room, and postoperative workflow. Alcon will showcase its digital offerings at the upcoming American Academy of Ophthalmology (AAO) 2023 annual meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
-
Rhea-AI Summary
Alcon (SIX/NYSE: ALC) announced the global launch of TOTAL30® Multifocal, the first and only monthly Water Gradient multifocal contact lens. The lenses provide excellent visual acuity at all distances, addressing the vision and comfort needs of the global multifocal market, a rapidly growing market valued over $1 billion globally and growing double digit annually. The lenses have begun to roll out in the United States and select international markets, offering Alcon's premium Water Gradient innovation at a more accessible price point of monthly lenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
none
-
Rhea-AI Summary
Alcon's Vivity Registry Study demonstrates excellent outcomes with AcrySof IQ Vivity and AcrySof IQ Vivity Toric
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Alcon presents scientific data and innovations at the 41st Congress of the European Society of Cataract and Refractive Surgeons (ESCRS). Alcon's intraocular lens and surgical equipment portfolio showcased, including the next generation in refractive surgery. Alcon expands Global Medical Affairs website to support eye care professionals in multiple countries. Alcon to host symposia and booth talks on various topics related to cataract surgery. Alcon sponsors ESCRS iNovation Day and near-live surgery sessions. Alcon emphasizes commitment to sustainability. Please refer to relevant products DFU or Operator’s manuals for complete list of indications, contraindications, and warnings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
none
Alcon Inc.

NYSE:ALC

ALC Rankings

ALC Stock Data

43.15B
492.24M
0.04%
63.98%
0.82%
Ophthalmic Goods Manufacturing
Manufacturing
Link
Switzerland
Vernier

About ALC

Alcon is an American Swiss medical company specializing in eye care products with headquarters in Geneva, Switzerland, and incorporated in Fribourg, Switzerland.